Business
-
Harm Reduction Therapeutics announced that it has signed a commercial supply agreement for its RiVive (HRT001) intranasal naloxone after the FDA granted Fast Track designation to the nasal spray, which is in development as a… Read more . . .
-
According to Tonix Pharmaceuticals, the United States Patent and Trademark Office has issued the company US Patent 11,389,473,”Magnesium-Containing Oxytocin Formulations and Methods of Use,” which includes claims related to the use of such formulations for… Read more . . .
-
Atossa Therapeutics said that it has completed the first three parts of a Phase 1/2a trial, which was announced in July 2021, but it will skip the remaining part. Part D had been expected to… Read more . . .
-
ARS Pharmaceuticals plans to merge with Silverback Therapeutics, the companies said, with the combined company focused on approval and launch of ARS’s Neffy (ARS-1) epinephrine nasal spray for the treatment of allergic reactions. Shareholders of… Read more . . .
-
SoftOx Solutions has announced that the European Defense Fund has awarded a 3-year grant of approximately NOK 97 million (~€9.6 million) to the company’s subsidiary SoftOx Defense Solutions (SDS) for development of an inhalation solution… Read more . . .
-
According to Liquidia, the US Patent Trial and Appeal Board (PTAB) has found that none of the claims included in US Patent No. 10,716,793, covering Tyvaso inhaled treprostinil, are valid. The company said that the PTAB ruling would have… Read more . . .
-
Florida-based startup Transpire Bio announced that it has signed an agreement with Recipharm for development of two inhaled candidates, TRB-1 and TRB-2, for the treatment of asthma and COPD. The company says that the two… Read more . . .
-
German digital health company VisionHealth has announced that it will “cooperate on distribution of inhalation platform Kata” with Boehringer Ingelheim in Germany. The Kata app uses artificial intelligence and augmented reality technology in conjunction with… Read more . . .
-
TFF Pharmaceuticals announced that it has leased a new 3,500+ square foot R&D facility in Austin, Texas, USA, that will house additional lab space, as well as equipment for the production of preclinical supplies, significantly expanding… Read more . . .
-
According to Theravance Biopharma, the company is selling its stake in Theravance Respiratory Company (TRC), which received royalties from sales of GSK’s Trelegy Ellipta fluticasone furoate / umeclidinium / vilanterol DPI. The deal with Royalty Pharma… Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 21-October 22: MVIC Symposium, Lund, Sweden
October 28-October 30: Deutches Aerosol Therapie Symposium (DATS), Marburg, Germany
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland